NASDAQ · AYTUHealthcarePharmaceuticals

AYTU BioPharma news

$2.20+1.38%
Close Sep 29, 2026 · split-adjusted
Articles · 30 days2English, de-duplicated
Positive00% of coverage
Neutral2100%
Negative00% of coverage

About AYTU BioPharma

Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates
Zacks Investment ResearchSep 22, 5:15 PM ETNeutral

While the company beat both EPS and revenue estimates with a significant 77.27% earnings surprise, the stock has significantly underperformed the market year-to-date (-18.3% vs S&P 500 +13.4%). The Zacks Rank #3 (Hold) rating and mixed estimate revisions suggest neutral near-term performance expectations despite the positive earnings beat.

Also mentions AYTU

Articles that tag AYTU but are mainly about other companies.

HeartSciences Inc. (HSCS) Reports Q1 Loss, Misses Revenue Estimates
Zacks Investment ResearchSep 14, 5:35 PM ETNeutral

Expected to report a quarterly loss of $0.22 per share with a year-over-year improvement of 15.4%. However, revenues are expected to decline 23.7% year-over-year, presenting mixed signals with no consensus estimate changes in the last 30 days.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology